Bamlanivimab is a monoclonal antibody granted Emergency Use Authorization (EUA) in November 2020 by FDA for COVID-19 therapy. Bamlanivimab is directed against the spike protein of SARS-CoV-2, designed to block the virus' attachment and entry into human cells.